The Role of Neuron-specific Enolase (NSE) and Thimidine Kinase (TK) Levels in Prediction of Efficacy of EGFR-TKIs in Patients with Advanced-stage NSCLC

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00076967" target="_blank" >RIV/00216224:14110/14:00076967 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11140/14:10272091 RIV/00669806:_____/14:10272091

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

The Role of Neuron-specific Enolase (NSE) and Thimidine Kinase (TK) Levels in Prediction of Efficacy of EGFR-TKIs in Patients with Advanced-stage NSCLC

Popis výsledku v původním jazyce

Background/Aim: Tumor biomarkers are used for diagnostics and follow-up monitoring of patients with non-small cell lung cancer (NSCLC). We focused on the predictive role of neuron-specific enolase (NSE) and thimidine kinase (TK) in patients with advanced-stage NSCLC treated with epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs). Patients and Methods: In a total of 163 patients with advanced-stage (IIIB or IV) NSCLC treated with EGFR-TKIs (erlotinib or gefitinib), pre-treatment levels of NSEand TK were measured. Results: We observed significantly shorter progression-free (PFS) and overall survival (OS) in patients with high NSE levels (p=0.002; p=0.003) and also in those with high TK levels (p=0.026; p=0.020). The multivariate Cox proportional hazards model confirmed that high NSE is a strong independent predictive factor for short PFS (hazard ratio; HR=2.36; p=0.003).

Název v anglickém jazyce

The Role of Neuron-specific Enolase (NSE) and Thimidine Kinase (TK) Levels in Prediction of Efficacy of EGFR-TKIs in Patients with Advanced-stage NSCLC

Popis výsledku anglicky

Background/Aim: Tumor biomarkers are used for diagnostics and follow-up monitoring of patients with non-small cell lung cancer (NSCLC). We focused on the predictive role of neuron-specific enolase (NSE) and thimidine kinase (TK) in patients with advanced-stage NSCLC treated with epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs). Patients and Methods: In a total of 163 patients with advanced-stage (IIIB or IV) NSCLC treated with EGFR-TKIs (erlotinib or gefitinib), pre-treatment levels of NSEand TK were measured. Results: We observed significantly shorter progression-free (PFS) and overall survival (OS) in patients with high NSE levels (p=0.002; p=0.003) and also in those with high TK levels (p=0.026; p=0.020). The multivariate Cox proportional hazards model confirmed that high NSE is a strong independent predictive factor for short PFS (hazard ratio; HR=2.36; p=0.003).

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Svazek periodika

34

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

6

Strana od-do

5193-5198

Kód UT WoS článku

000341860700076

EID výsledku v databázi Scopus

—